Muna Albayaty

556 total citations
27 papers, 301 citations indexed

About

Muna Albayaty is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Muna Albayaty has authored 27 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Physiology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Muna Albayaty's work include Asthma and respiratory diseases (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Muna Albayaty is often cited by papers focused on Asthma and respiratory diseases (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Muna Albayaty collaborates with scholars based in United Kingdom, United States and Spain. Muna Albayaty's co-authors include Fredrik Tiberg, Håkan Olsson, Margareta Linden, Markus Johnsson, Hans Ericsson, Michael Kjær, Mary Birchler, Andrew I. Bayliffe, Adrian Serone and M. Claire Holland and has published in prestigious journals such as The Journal of Infectious Diseases, Annals of Oncology and Anesthesia & Analgesia.

In The Last Decade

Muna Albayaty

19 papers receiving 294 citations

Peers

Countries citing papers authored by Muna Albayaty

Since Specialization

Citations

This map shows the geographic impact of Muna Albayaty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muna Albayaty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muna Albayaty more than expected).

Fields of papers citing papers by Muna Albayaty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muna Albayaty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muna Albayaty. The network helps show where Muna Albayaty may publish in the future.

Co-authorship network of co-authors of Muna Albayaty

This figure shows the co-authorship network connecting the top 25 collaborators of Muna Albayaty. A scholar is included among the top collaborators of Muna Albayaty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muna Albayaty. Muna Albayaty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), Jiang Zhu, Chee Khoon Lee, Isamu Okamoto, (unknown), S-W. Kim, (unknown), Igor Andrašina, (unknown), (unknown), (unknown), (unknown), Jacqulyne Robichaux, (unknown), Edgar Monterroso, Muna Albayaty, (unknown)	0
2	Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study 2025 ·Lung Cancer ·Marina Chiara Garassino, Yong He, Myung‐Ju Ahn, Sergey Orlov, Vanessa Potter, Terufumi Kato, Janessa Laskin, Pei Jye Voon, Thanyanan Reungwetwattana, Suresh S. Ramalingam, Yi‐Long Wu, Muna Albayaty, (unknown), Xiangning Huang, (unknown), Byoung Chul Cho	0
3	MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC 2024 ·Journal of Thoracic Oncology ·Natalia Valdiviezo, (unknown), Pasi A. Jänne, (unknown), (unknown), Ying Cheng, Chee Khoon Lee, (unknown), Yu Yao, Tae Min Kim, (unknown), Muna Albayaty, (unknown), (unknown)	5
4	630MO First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort 2024 ·Annals of Oncology ·James Chih‐Hsin Yang, Kunihiko Kobayashi, (unknown), (unknown), Bivas Biswas, (unknown), (unknown), Xuan Dung Pham, Yu Yao, Shoichi Kuyama, (unknown), (unknown), M-J. Ahn, Virote Sriuranpong, (unknown), Edgar Monterroso, (unknown), Muna Albayaty, Ying Cheng	1
5	Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults 2023 ·The Journal of Infectious Diseases ·(unknown), Muna Albayaty, Dennis Brooks, Rosalinda H. Arends, (unknown), Anastasia A. Aksyuk, Jérôme Bouquet, Cecil Chen, (unknown), Robert Kubiak, Venkatesh Pilla Reddy, (unknown), Katie Streicher, Alison Templeton, Mark T. Esser	11
6	Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial 2023 ·Journal of Thoracic Oncology ·Thomas John, Christian Grohé, Jonathan W. Goldman, Frances A. Shepherd, Filippo de Marinis, Terufumi Kato, Qun Wang, Wu‐Chou Su, Jin‐Hyuk Choi, Virote Sriuranpong, Barbara Melotti, Mary J. Fidler, Jun Chen, Muna Albayaty, Marta Stachowiak, (unknown), Yi‐Long Wu, Masahiro Tsuboi, Roy S. Herbst, Margarita Majem	14
7	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects 2021 ·Clinical Pharmacokinetics ·Andreas B. Jordy, Muna Albayaty, Astrid Breitschaft, Thomas W. Anderson, Erik Christiansen, (unknown), (unknown), Tine A. Bækdal	11
8	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges 2020 ·Frontiers in Pharmacology ·(unknown), Muna Albayaty, James Bush, Joseph Cheriyan, (unknown), Annelize Koch, Michael Hammond, Stuart Mair, Ulrike Lorch, (unknown), Jörg Täubel, Timothy C. Hardman	0
9	Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator 2020 ·Respiratory Research ·(unknown), Carol Astbury, Muna Albayaty, Ulrika Wählby Hamrén, Beatriz Seoane, (unknown), (unknown), (unknown), Ajay Aggarwal, Ioannis Psallidas	0
10	Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies 2020 ·Respiratory Research ·(unknown), Muna Albayaty, (unknown), Ulrika Wählby Hamrén, Carol Astbury, Beatriz Seoane, Marie‐Pierre Malice, (unknown), Ajay Aggarwal, Ioannis Psallidas	0
11	Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent 2020 ·Pharmacology Research & Perspectives ·Lindsey Cass, Alison D. Murray, Amanda Davis, Kathy Woodward, Muna Albayaty, Kazuhiro Ito, Pete Strong, John Ayrton, Charlie Brindley, (unknown), John C. Murray, (unknown), (unknown), Christopher Wallis, Garth Rapeport	47
12	The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial 2019 ·Clinical Pharmacology in Drug Development ·Shaila Shabbir, Isabelle Pouliquen, Jane H. Bentley, Eric Bradford, Morrys C. Kaisermann, Muna Albayaty	14
13	Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study 2019 ·Clinical and Translational Science ·Andrew K. Whittaker, (unknown), (unknown), Muna Albayaty, (unknown), Peter J. Greasley, Maria Heijer, Michael Kjær, Pablo Forte, Robert J. Unwin, (unknown), Hans Ericsson	24
14	The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial 2019 ·(unknown), Isabelle Pouliquen, Jane H. Bentley, Eric Bradford, (unknown), Muna Albayaty	1
15	Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting 2019 ·Anesthesia & Analgesia ·Gabriel Fox, Muna Albayaty, (unknown), (unknown), Börje Darpö	12
16	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development 2018 ·Frontiers in Pharmacology ·Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, (unknown), Annelize Koch, Michael Hammond, Stuart Mair, Peter Scholes, Ulrike Lorch, (unknown), Jörg Täubel, Timothy C. Hardman	1
17	P138 Urinary leukotriene E4 (uLTE4) pharmacodynamic biomarker for early decision making in the AZD9898 adaptive phase i study 2018 ·Joanne Betts, B. Larsson, Alexandra Jauhiainen, (unknown), (unknown), Alessandro Maria Berton, Pernilla Glader, (unknown), (unknown), Jessica Franzén, Muna Albayaty, Christina Keen, (unknown)	0
18	Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study 2017 ·Advances in Therapy ·Muna Albayaty, Margareta Linden, Håkan Olsson, Markus Johnsson, (unknown), Fredrik Tiberg	46
19	A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics 2017 ·(unknown), Carol Astbury, Beatriz Seoane, (unknown), (unknown), (unknown), Ajay Aggarwal, Muna Albayaty	2
20	Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 2013 ·Journal of Clinical Immunology ·M. Claire Holland, Jens Würthner, Peter J. Morley, Mary Birchler, John M. Lambert, Muna Albayaty, Adrian Serone, Robert C. Wilson, (unknown), (unknown), (unknown), David A. Lipson, Andrew I. Bayliffe	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact